Interleukin-21 engineering enhances CD19-specific CAR-NK cell activity against B-cell lymphoma via enriched metabolic pathways
This study demonstrated that CD19-specific CAR-NK cells engineered to express IL-21 exhibit superior persistence and anti-tumor activity against CD19<sup>+</sup> tumor compared to CAR-NK cells co-expressing IL-15, which might be a promising therapeutic strategy for treating patients with relapse or refractory B cell malignances.
Authors
- Chengyao Li
- Qifa Liu (ORCID: https://orcid.org/0000-0003-4015-3952)
- Hongsheng Zhou (ORCID: https://orcid.org/0000-0002-4888-7021)
- Jiaxu Wu
- Shikai Deng (ORCID: https://orcid.org/0000-0002-1895-2072)
- Bailin He (ORCID: https://orcid.org/0000-0003-3904-1945)
- Qing Zeng
- Shiqiu Qiu
- Hong Chen (ORCID: https://orcid.org/0000-0001-5528-3923)
- Xuan Li (ORCID: https://orcid.org/0000-0001-9352-6375)
- Xiaoli Liu (ORCID: https://orcid.org/0000-0003-1686-3292)
- Cong Wang
- Na Xu (ORCID: https://orcid.org/0000-0003-3708-5741)
- Qiusui Mai
- Zihong Cai (ORCID: https://orcid.org/0009-0005-4848-9508)
Institutions
- Sun Yat-sen University (CN)
- The Seventh Affiliated Hospital of Sun Yat-sen University (CN)
- Nanfang Hospital (CN)
- First Affiliated Hospital of Guangdong Pharmaceutical University (CN)
- Southern Medical University (CN)
Publication Details
- Journal
- Experimental Hematology and Oncology
- Published
- 2025-04-02
- DOI
- https://doi.org/10.1186/s40164-025-00639-2
- Citations
- 5
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 5.23
Funders
- National Natural Science Foundation of China
- China Postdoctoral Science Foundation
- Basic and Applied Basic Research Foundation of Guangdong Province